Avalon Globocare Corp :Avalon Globocare Signs Definitive Agreement For Transformational Acquisition Of Leading Laboratory With 2021 Unaudited Revenue In Excess Of $25 Million.Company To Begin Trading Under New Symbol "Albt" On November 10, 2022.Total Consideration For Acquisition Will Be $31 Million.Avalon Globocare - Deal Cash Portion To Be Financed With Private Placement Of $15 Million Of Preferred Stock, Convertible At A Floor Of $1.00 Per Share.Shares Of Co'S Common Stock Will Begin Trading Under New Ticker Symbol "Albt" On Nasdaq Capital Market On Thursday, Nov 10.Sarah Cox, Co-Founder And Ceo Of Laboratory Services, Will Become Chief Operating Officer Of Company.Has Signed A Definitive Acquisition Agreement To Acquire A 60% Interest In Laboratory Services Mso, Llc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。